Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ICON Public Limited Company    ICLR   IE0005711209


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ICON : Launches Accellacare a Global Clinical Research Network Focused on Increasing Patient Recruitment With a Patient Centric Approach

09/03/2020 | 04:31am EST

Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials

ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, today announced that it is launching Accellacare a global clinical research network offering patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. The site network includes previously acquired PMG Research in the US and MeDiNova Research in EMEA.

Accellacare’s patient centric approach focusing on enhancing the patient experience and providing patient assessments either at site, or at home as part of integrated operations with Symphony Clinical Research, the leading global provider of at-home care and nursing for clinical trials owned by ICON, is leading to higher recruitment and retention rates. Accellacare is also achieving faster study start-up for its customers through efficiencies gained in central process management including budget and contracting, which can otherwise be a source of delay. This combined with a finely tuned feasibility approach ensures that the network can identify and recruit more patients to studies, in a wide range of therapeutic areas, in a shorter time frame

Dr. Steve Cutler, Chief Executive Officer, ICON plc, said: “Accellacare is an important part of our integrated patient, site and data strategy, helping us to improve patient recruitment and retention. Accellacare is committed to delivering on the promise of patient centricity in clinical research which is bringing benefits to both patients and sponsors. It is also providing investigators with innovative treatments for their patients with a quality-focused clinical research infrastructure supported by experienced professionals globally.”

About Accellacare
Accellacare is a global clinical research network increasing patient recruitment and retention with a patient centric approach. The Accellacare feasibility and central process management enables faster study start-up and its dedicated patient engagement team drives identification and recruitment of suitable patients, using an extensive database of patients and targeted campaigns, resulting in higher recruitment levels per site. Accellacare extends across the globe with 77 active research sites in seven countries with particular expertise in 12 therapeutic areas. It has relationships with 275 Principal Investigators connecting it to 8 million+ patients.

Further information is available at www.accellacare.com

About ICON plc
ICON plc is a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 94 locations in 40 countries and has approximately 15,150 employees as of June 30, 2020.

Further information is available at www.iconplc.com/sites

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.


© Business Wire 2020
01/12ICON PUBLIC : plc Presentation
01/07ICON PLC : to Present at the 39th Annual JP Morgan Healthcare Conference
01/04ICON PUBLIC : Supports Pfizer and BioNTech on the Investigational COVID-19 Vacci..
2020ICON PUBLIC : Releases First Environmental, Social and Governance Report
2020ICON PLC : to Present at the 29th Annual Credit Suisse Virtual Healthcare Confer..
2020ICON PUBLIC : plc Q3 2020 Presentation
2020ICON PUBLIC : Reports Third Quarter 2020 Results
2020ICON PUBLIC : BARDA reselects ICON as preferred partner to help strengthen US em..
2020ICON PUBLIC : Wins Best CRO at the Vaccine Industry Excellence Awards
2020ICON : Launches Accellacare a Global Clinical Research Network Focused on Increa..
More news
Financials (USD)
Sales 2020 2 789 M - -
Net income 2020 330 M - -
Net cash 2020 309 M - -
P/E ratio 2020 34,1x
Yield 2020 -
Capitalization 11 101 M 11 101 M -
EV / Sales 2020 3,87x
EV / Sales 2021 3,35x
Nbr of Employees 15 250
Free-Float 98,5%
Duration : Period :
ICON Public Limited Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ICON PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 206,29 $
Last Close Price 210,35 $
Spread / Highest target 14,1%
Spread / Average Target -1,93%
Spread / Lowest Target -27,7%
EPS Revisions
Managers and Directors
Stephen A. Cutler Chief Executive Officer & Executive Director
Ciaran Murray Executive Chairman
Brendan Brennan Chief Financial Officer
Tom O'Leary Chief Information Officer
Anthony J. Japour Medical Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
SEAGEN INC.6.06%33 601